[1]Tong SY,Davis JS,Eichenberger E,et al.Staphylococcus aureus infections:epidemiology,pathophysiology,clinical manifestations,and management[J].Clin Microbiol Rev,2015,28(3):603-661.
[2]陈志,周宗科,沈彬,等.急性、迟发性、慢性假体周围感染的病原学特征及疗效分析[J].实用骨科杂志,2019,25(4):313-316.
[3]Foster TJ,Geoghegan JA,Ganesh VK,et al.Adhesion,invasion and evasion:the many functions of the surface proteins of Staphylococcus aureus[J].Nat Rev Microbiol,2014,12(1):49-62.
[4]Josse J,Velard F,Gangloff SC.Staphylococcus aureus vs.osteoblast:relationship and consequences in osteomyelitis[J].Front Cell Infect Microbiol,2015(5):85.
[5]Jönsson K,McDevitt D,McGavin MH,et al.Staphylococcus aureus expresses a major histocompatibility complex class Ⅱ analog[J].J Biol Chem,1995,270(37):21457-21460.
[6]Alva-Murillo N,López-Meza JE,Ochoa-Zarzosa A.Nonprofessional phagocytic cell receptors involved in Staphylococcus aureusinternalization[J].Biomed Res Int,2014(2014):538546.
[7]Horn J,Stelzner K,Rudel T,et al.Inside job:Staphylococcus aureus host-pathogen interactions[J].Int J Med Microbiol,2018,308(6):607-624.
[8]Hamza T,Li B.Differential responses of osteoblasts and macrophages upon Staphylococcus aureusinfection[J].BMC Microbiol,2014(14):207.
[9]Tuchscherr L,Kreis CA,Hoerr V,et al.Staphylococcus aureus develops increased resistance to antibiotics by forming dynamic small colony variants during chronic osteomyelitis[J].J Antimicrob Chemother,2016,71(2):438-448.
[10]Tuchscherr L,Bischoff M,Lattar SM,et al.Sigma factor sigBis crucial to mediate staphylococcus aureusadaptation during chronic infections[J].PLoSPathog,2015,11(4):e1004870.
[11]Lauderdale KJ,Boles BR,Cheung AL,et al.Interconnections between sigma B,agr,and proteolytic activity in staphylococcus aureusbiofilm maturation[J].Infect Immun,2009,77(4):1623-1635.
[12]Kahl BC.Small colony variants (SCVs) of Staphylococcus aureus--a bacterial survival strategy[J].Infect Genet Evol,2014(21):515-522.
[13]Dapunt U,Maurer S,Giese T,et al.The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis:linking inflammation to bone degradation[J].Mediators Inflamm,2014(2014):728619.
[14]Zhu C,Wang J,Cheng T,et al.The potential role of increasing the release of mouse β-defensin-14 in the treatment of osteomyelitis in mice:a primary study[J].PLoS One,2014,9(1):e86874.
[15]Hall-Stoodley L,Costerton JW,Stoodley P.Bacterial biofilms:from the natural environment to infectious diseases[J].Nat Rev Microbiol,2004,2(2):95-108.
[16]Schwartz K,Ganesan M,Payne DE,et al.Extracellular DNA facilitates the formation of functional amyloids in Staphylococcus aureus biofilms[J].Mol Microbiol,2016,99(1):123-134.
[17]Sugimoto S,Sato F,Miyakawa R,et al.Broad impact of extracellular DNA on biofilm formation by clinically isolated Methicillin-resistant and sensitive strains of Staphylococcus aureus[J].Sci Rep,2018,8(1):2254.
[18]Lister JL,Horswill AR.Staphylococcus aureus biofilms:recent developments in biofilm dispersal[J].Front Cell Infect Microbiol,2014(4):178.
[19]Rabin N,Zheng Y,OpokuTemeng C,et al.Biofilm formation mechanisms and targets for developing antibiofilm agents[J].Future Med Chem,2015,7(4):493-512.
[20]Suresh MK,Biswas R,Biswas L.An update on recent developments in the prevention and treatment of Staphylococcus aureusbiofilms[J].IntJ Med Microbiol,2019,309(1):1-12.
[21]Moormeier DE,Bayles KW.Staphylococcus aureus biofilm:a complex developmental organism[J].MolMicrobiol,2017,104(3):365-376.
[22]Otto M.Staphylococcal infections:mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity[J].Annu Rev Med,2013(64):175-188.
[23]Busscher HJ,van der Mei HC.How do bacteria know they are on a surface and regulate their response to an adhering state?[J].PLoS Pathog,2012,8(1):e1002440.
[24]Scherr TD,Heim CE,Morrison JM,et al.Hiding in plain sight:interplay between staphylococcal biofilms and host immunity[J].Front Immunol,2014(5):37.
[25]Hogan A,Heppert VG,Suda AJ.Osteomyelitis[J].Arch Orthop Trauma Surg,2013,133(9):1183-1196.
[26]González-Galván MC,Mosqueda-Taylor A,Bologna-Molina R,et al.Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenicmyxomas[J].Med Oral Patol Oral Cir Bucal,2018,23(3):e315-e319.
[27]Sanchez CJ Jr,Ward CL,Romano DR,et al.Staphylococcus aureus biofilms decrease osteoblast viability,inhibits osteogenic differentiation,and increases bone resorption in vitro[J].BMC Musculoskelet Disord,2013(14):187.
[28]Davido B,Saleh-Mghir A,Laurent F,et al.Phenol-soluble modulinscontribute to early sepsis dissemination not late local USA300-osteomyelitis severity in rabbits[J].PLoS One,2016,11(6):e0157133.
[29]Kassem A,Lindholm C,Lerner UH.Toll-like receptor 2 stimulation of osteoblasts mediates staphylococcus aureusinduced bone resorption and osteoclastogenesis through enhanced RANKL[J].PLoS One,2016,11(6):e0156708.
[30]Trouillet-Assant S,Gallet M,Nauroy P,et al.Dual impact of live Staphylococcus aureus on the osteoclast lineage,leading to increased bone resorption[J].J Infect Dis,2015,211(4):571-581.
[31]Kavanagh N,Ryan EJ,Widaa A,et al.Staphylococcal osteomyelitis:disease progression,treatment challenges,and future directions[J].Clin Microbiol Rev,2018,31(2):84-117.
[32]张震,魏屹东,季明华,等.胫骨慢性骨髓炎治疗进展[J].实用骨科杂志,2019,25(2):146-149.
[33]Yang S,Han X,Yang Y,et al.Bacteria-targeting nanoparticles with microenvironment-responsive antibiotic release to eliminate intracellular staphylococcus aureus and associated infection[J].ACS Appl Mater Interfaces,2018,10(17):14299-14311.
[34]Mu H,Tang J,Liu Q,et al.Potent antibacterial nanoparticles against biofilm and intracellular bacteria[J].Sci Rep,2016(6):18877.
[35]Selan L,Papa R,Ermocida A,et al.Serratiopeptidase reduces the invasion of osteoblasts by Staphylococcus aureus[J].Int J Immunopathol Pharmacol,2017,30(4):423-428.
[36]Bhattacharya M,Wozniak DJ,Stoodley P,et al.Prevention and treatment of staphylococcus aureus biofilms[J].Expert Rev Anti Infect Ther,2015,13(12):1499-1516.
[37]Saginur R,Stdenis M,Ferris W,et al.Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections[J].Antimicrob Agents Chemother,2006,50(1):55-61.
[38]Zhou Y,Zhao R,Ma B,et al.Oligomerization of RNAⅢ-inhibiting peptide inhibits adherence and biofilm formation of methicillin-resistant staphylococcus aureusin vitro and in vivo[J].Microb Drug Resist,2016,22(3):193-201.
[39]Zapotoczna M,Forde É,Hogan S,et al.Eradication of staphylococcus aureusbiofilm infections using synthetic antimicrobial peptides[J].J Infect Dis,2017,215(6):975-983.
[40]Jorge P,Grzywacz D,Kamysz W,et al.Searching for new strategies against biofilm infections:Colistin-AMP combinations against pseudomonas aeruginosa and staphylococcus aureus single-and double-species biofilms[J].PLoS One,2017,12(3):e0174654.
[41]Ahn KB,Baik JE,Yun CH,et al.Lipoteichoicacid inhibits staphylococcus aureusbiofilm formation[J].Front Microbiol,2018(9):327.
[42]Qi X,Zhao Y,Zhang J,et al.Increased effects of extracorporeal shock waves combined with gentamicin against staphylococcus aureusbiofilms in vitro and in vivo[J].Ultrasound Med Biol,2016,42(9):2245-2252.
[43]Barra F,Roscetto E,Soriano AA,et al.Photodynamic and antibiotic therapy in combination to fight biofilms and resistant surface bacterial infections[J].Int J MolSci,2015,16(9):20417-20430.